vTv Therapeutics (VTVT) Equity Average (2016 - 2025)
Historic Equity Average for vTv Therapeutics (VTVT) over the last 11 years, with Q3 2025 value amounting to $36.7 million.
- vTv Therapeutics' Equity Average rose 9114.73% to $36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.7 million, marking a year-over-year increase of 9114.73%. This contributed to the annual value of -$5.2 million for FY2024, which is 7069.73% up from last year.
- Per vTv Therapeutics' latest filing, its Equity Average stood at $36.7 million for Q3 2025, which was up 9114.73% from $5.8 million recorded in Q2 2025.
- In the past 5 years, vTv Therapeutics' Equity Average ranged from a high of $36.7 million in Q3 2025 and a low of -$68.2 million during Q1 2021
- Moreover, its 5-year median value for Equity Average was -$12.5 million (2022), whereas its average is -$9.9 million.
- In the last 5 years, vTv Therapeutics' Equity Average tumbled by 16761.54% in 2023 and then skyrocketed by 167490.44% in 2025.
- Over the past 5 years, vTv Therapeutics' Equity Average (Quarter) stood at -$15.6 million in 2021, then increased by 12.71% to -$13.7 million in 2022, then tumbled by 82.77% to -$25.0 million in 2023, then surged by 164.54% to $16.1 million in 2024, then soared by 127.56% to $36.7 million in 2025.
- Its last three reported values are $36.7 million in Q3 2025, $5.8 million for Q2 2025, and $11.6 million during Q1 2025.